ASH 2022 | Updates from LINKER-MM1: safety and efficacy of linvoseltamab in patients with R/R multiple myeloma
In this video, Naresh Bumma, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, shares updated safety and efficacy data from the Phase I/II LINKER-MM1 study (NCT03761108) of linvoseltamab, a BCMAxCD3 bispecific antibody, for relapsed/refractory (R/R) multiple myeloma. Overall, linvoseltamab demonstrated promising efficacy and an acceptable safety profile in patients with heavily pre-treated R/R multiple myeloma. All adverse events (AEs) recorded in the study were predictable and/ or manageable, with anemia and cytokine release syndrome (CRS) being the most common AEs noted. Dr Bumma outlines that most patients had a durable response to the treatment, with many achieving measurable residual disease (MRD) negativity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Membership on an entity’s Board of Directors or advisory committees, Other: Ad Board; Sanofi, Genzyme: Other: Ad Board, Speakers Bureau; Amgen: Consultancy, Speakers Bureau
